AZN sentiment intelligence

Kavout Direct company coverage

Why Did AstraZeneca (AZN) Stock Dip More Than the Market Today

AstraZeneca (AZN) shares dipped 1.35% today, slightly underperforming the broader market due to a confluence of factors including ongoing concerns about its China subsidiary and recent analyst downgrades. Despite these short-term pressures and valuation scrutiny, the company main

Tone

Neutral 50/100

Event

Balance sheet

Published

21 Jun 2026 05:09

Source

Kavout

MarketWatch Direct company coverage

AstraZeneca slides Thursday, underperforms market

AstraZeneca PLC (AZN) shares fell 2.36% on Thursday to £131.54, underperforming the broader market as the FTSE 100 Index declined by 1.04%. The company's stock closed 16.39% below its 52-week high, which was recorded on February 18th.

Tone

Neutral 50/100

Event

Market update

Published

18 Jun 2026 12:06

Source

MarketWatch

MarketWatch Direct company coverage

AstraZeneca rallies Wednesday, outperforms market

AstraZeneca PLC (AZN) shares rose 1.42% to £134.72 on Wednesday, outperforming the broader market as the FTSE 100 Index also saw gains. The pharmaceutical company's stock closed 14.37% below its 52-week high of £157.32, which was reached on February 18th.

Tone

Positive 62/100

Event

Market update

Published

17 Jun 2026 12:07

Source

MarketWatch

Market source Direct company coverage

The Zacks Analyst Blog Highlights Applied Materials, GE, AstraZeneca, Team and Applied Energetics

This Zacks Analyst Blog highlights research reports on five companies: Applied Materials Inc. (AMAT), GE Aerospace (GE), AstraZeneca PLC (AZN), Team, Inc. (TISI), and Applied Energetics Inc. (AERG). It details the financial performance and future outlook for each company, noting

Tone

Positive 64/100

Event

Guidance

Published

17 Jun 2026 07:11

Source

Market source

Stock Titan Direct company coverage

AstraZeneca (AZN) officer receives Ordinary Share award under incentive plan

A AstraZeneca (AZN) officer, Mani Sharma, received 1 Ordinary Share as a compensation grant under the company’s Share Incentive Plan. This award was valued at $179.75 per share, based on a GBP134.54 price and a GBP1.0000 to $1.3360 conversion rate. Following this transaction, Sha

Tone

Neutral 50/100

Event

Market update

Published

17 Jun 2026 03:09

Source

Stock Titan

TradingView Direct company coverage

AstraZeneca Stock Down 7% in 3 Months: Should You Buy, Sell or Hold?

AstraZeneca's stock has dropped 7.4% in the last three months, largely due to a pipeline setback involving its breast cancer drug candidate, camizestrant. Despite this, the company boasts a strong portfolio of 16 blockbuster drugs, significant growth in its oncology segment, and

Tone

Neutral 50/100

Event

Market update

Published

16 Jun 2026 14:09

Source

TradingView

Market source Direct company coverage

AstraZeneca's Truqap Wins FDA Nod for Prostate Cancer Indication

AstraZeneca's Truqap (capivasertib) has received FDA approval for an expanded prostate cancer indication, making it the first AKT inhibitor approved in a second tumor type. The approval is for its use in combination with J&J’s Zytiga and prednisone for PTEN-deficient mAPMN/S pros

Tone

Positive 71/100

Event

Regulatory and legal

Published

16 Jun 2026 02:40

Source

Market source

Clinical Trials Arena Direct company coverage

EHA26: AstraZeneca battles Roche in untreated follicular lymphoma

AstraZeneca presented preliminary safety data for its pipeline drug surovatamig at the 2026 European Hematological Association conference, aiming to provide a chemotherapy-free regimen for untreated advanced follicular lymphoma. This drug, acquired from TeneoTwo, is currently bei

Tone

Positive 66/100

Event

Market update

Published

16 Jun 2026 02:40

Source

Clinical Trials Arena

www.marketscreener.com Direct company coverage

ASTRAZENECA : Gets a Buy rating from Jefferies

Jefferies has issued a "Buy" rating for AstraZeneca PLC, maintaining its target price at GBX 18000. This positive analyst recommendation suggests confidence in the pharmaceutical company's stock performance.

Tone

Positive 87/100

Event

Analyst action

Published

16 Jun 2026 01:21

Source

www.marketscreener.com

TheStreet Direct company coverage

AstraZeneca says AI is raising its odds where most drugs fail

AstraZeneca CEO Pascal Soriot claims that artificial intelligence is improving the company's success rate in drug development, particularly at the costly Phase 3 trial stage where most drugs fail. Drug development is a notoriously expensive and high-risk endeavor, with only 10% o

Tone

Positive 70/100

Event

Market update

Published

15 Jun 2026 21:37

Source

TheStreet

Benzinga Direct company coverage

This Aggressive Prostate Cancer Finally Has Targeted Treatment — AstraZeneca Wins FDA Nod

AstraZeneca received FDA approval for Truqap, making it the first targeted treatment option for PTEN-deficient metastatic prostate cancer. This approval is supported by findings from the Phase III CAPItello-281 trial, showing a significant reduction in disease progression risk. A

Tone

Positive 72/100

Event

Regulatory and legal

Published

15 Jun 2026 16:40

Source

Benzinga

MarketWatch Direct company coverage

AstraZeneca slips Monday, underperforms market

AstraZeneca PLC (AZN) shares fell by 1.95% on Monday, closing at £132.00, while the broader FTSE 100 Index also experienced a decline. This performance places AstraZeneca 16.09% below its 52-week high reached in February. The article highlights the company's underperformance in a

Tone

Negative 29/100

Event

Market update

Published

15 Jun 2026 12:07

Source

MarketWatch

Stock Titan Direct company coverage

US approves AstraZeneca (NYSE: AZN) Truqap combo for PTEN-deficient metastatic prostate cancer

AstraZeneca's Truqap (capivasertib), in combination with abiraterone and prednisone, has received US FDA approval for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prostate cancer. This marks the first targeted therapy for this aggre

Tone

Positive 73/100

Event

Regulatory and legal

Published

15 Jun 2026 10:39

Source

Stock Titan

DirectorsTalk Interviews Direct company coverage

Astrazeneca Plc Gains US Approval For Truqap In PTEN-deficient Prostate Cancer

AstraZeneca's Truqap, combined with abiraterone and prednisone, has received US FDA approval as the first targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prostate cancer. This approval is based on positive result

Tone

Positive 93/100

Event

Regulatory and legal

Published

15 Jun 2026 06:39

Source

DirectorsTalk Interviews

Seeking Alpha Direct company coverage

AstraZeneca Truqap Ok'd in U.S. for prostate cancer (AZN:NYSE)

AstraZeneca announced that the U.S. FDA has approved a label expansion for its anti-tumor agent Truqap (capivasertib). This approval allows Truqap to be used in a combination regimen for a specific type of prostate cancer. The medication will be available as a twice-daily pill.

Tone

Positive 76/100

Event

Regulatory and legal

Published

12 Jun 2026 18:38

Source

Seeking Alpha

www.marketscreener.com Direct company coverage

AstraZeneca : Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

AstraZeneca's Truqap (capivasertib), in combination with abiraterone and prednisone, has received FDA approval in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate ca

Tone

Positive 73/100

Event

Regulatory and legal

Published

12 Jun 2026 18:08

Source

www.marketscreener.com

Market source Direct company coverage

Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know

Astrazeneca (AZN) saw a gain of 1.86% in its latest session, outperforming the S&P 500. Despite recent underperformance over the past month, analysts anticipate its upcoming earnings report to show $2.1 per share, with full fiscal year projections indicating growth. The company c

Tone

Positive 61/100

Event

Earnings

Published

11 Jun 2026 22:09

Source

Market source

Citeline News & Insights Direct company coverage

ADA 2026: AstraZeneca To Move Fast On Obesity And Heart Pill Combinations

AstraZeneca is expected to rapidly advance its development of combination therapies for obesity and heart conditions. The company's strategy involves combining existing cardiovascular and renal drugs with new obesity treatments. This move is anticipated to be a major topic at the

Tone

Positive 67/100

Event

Market update

Published

10 Jun 2026 16:40

Source

Citeline News & Insights

Benzinga Direct company coverage

AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials

AstraZeneca's oral GLP-1 receptor agonist, elecoglipron, is advancing to Phase 3 trials following strong results in two Phase 2b studies for weight loss and Type 2 diabetes. The VISTA trial showed an average weight reduction of 10.5% in obese or overweight participants, while the

Tone

Positive 72/100

Event

Earnings

Published

09 Jun 2026 16:10

Source

Benzinga

Clinical Trials Arena Direct company coverage

ADA26: AstraZeneca unveils positive data for Phase III-ready oral GLP-1RA

AstraZeneca has announced positive Phase IIb trial results for elecoglipron, an oral GLP-1RA, showing significant weight loss in obesity patients and improved HbA1c levels in type 2 diabetes patients. These results pave the way for Phase III trials, positioning AstraZeneca to ent

Tone

Neutral 50/100

Event

Earnings

Published

09 Jun 2026 11:09

Source

Clinical Trials Arena

www.marketscreener.com Direct company coverage

AstraZeneca : Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney portfolio

AstraZeneca's oral GLP-1 RA, elecoglipron, is advancing to a Phase III program following positive Phase IIb trial results for obesity and type 2 diabetes. In the VISTA trial, patients with obesity or overweight achieved significant weight loss and improved cardiometabolic risk fa

Tone

Positive 75/100

Event

Earnings

Published

08 Jun 2026 20:40

Source

www.marketscreener.com

Investing.com Nigeria Direct company coverage

AstraZeneca’s oral GLP-1 advances to Phase III after strong trial results

AstraZeneca's oral GLP-1 receptor agonist elecoglipron is moving to Phase III clinical trials following positive results from two mid-stage trials. The drug demonstrated significant weight loss and blood sugar reduction in adults with obesity/overweight and type 2 diabetes, respe

Tone

Positive 71/100

Event

Earnings

Published

08 Jun 2026 20:40

Source

Investing.com Nigeria

Citeline News & Insights Direct company coverage

ADA 2026: AstraZeneca Advances Oral GLP-1 Elecoglipron Into Phase III After Positive Trial Data

AstraZeneca has announced the advancement of its oral GLP-1 receptor agonist, Elecoglipron, into Phase III clinical trials. This decision follows positive data from earlier trials, highlighting AstraZeneca's focus on cardiovascular, renal, and metabolism (CVRM) as a key growth ar

Tone

Positive 71/100

Event

Market update

Published

08 Jun 2026 20:40

Source

Citeline News & Insights

FirstWord Pharma Direct company coverage

AstraZeneca unveils data behind Phase III-bound oral GLP-1

AstraZeneca has unveiled data supporting its Phase III-bound oral GLP-1 receptor agonist, danuglipron. The company is positioning danuglipron as a potential strong competitor in the rapidly growing obesity and diabetes market. This oral GLP-1 is expected to enter late-stage clini

Tone

Positive 65/100

Event

Market update

Published

08 Jun 2026 20:40

Source

FirstWord Pharma

Bloomberg.com Direct company coverage

Astra Obesity Pill Delivers 11.8% Weight Loss in Mid-Stage Trial

AstraZeneca's experimental obesity pill, elecoglipron, demonstrated an 11.8% body weight loss in a mid-stage clinical trial. This positions AstraZeneca to enter the growing weight-loss drug market, though its pill showed less efficacy compared to rival drugs from Eli Lilly and No

Tone

Positive 65/100

Event

Market update

Published

08 Jun 2026 20:15

Source

Bloomberg.com

Benzinga Direct company coverage

AstraZeneca Reports Significant Proteinuria Reduction With Ultomiris In Rare Kidney Disease

AstraZeneca's Ultomiris (ravulizumab) has demonstrated a significant and early reduction in proteinuria in adults with immunoglobulin A nephropathy (IgAN) at risk of disease progression, according to interim results from the Phase 3 I CAN trial. Patients treated with Ultomiris ex

Tone

Positive 66/100

Event

Earnings

Published

08 Jun 2026 16:40

Source

Benzinga

MarketWatch Direct company coverage

AstraZeneca advances Friday, outperforms market

AstraZeneca PLC (AZN) shares advanced 2.24% to £138.58 on Friday, outperforming the FTSE 100 Index. The increase occurred during a favorable trading session, with the FTSE 100 rising 0.07%. AstraZeneca's closing price was 11.91% below its 52-week high.

Tone

Positive 75/100

Event

Market update

Published

05 Jun 2026 12:06

Source

MarketWatch

MarketWatch Direct company coverage

AstraZeneca advances Thursday, outperforms market

AstraZeneca PLC shares rose 2.60% to £135.54 on Thursday, outperforming the broader market as the FTSE 100 Index also saw a modest rise. The company's stock closed 13.84% below its 52-week high of £157.32, which was reached in February. This performance occurred on an overall pos

Tone

Positive 71/100

Event

Market update

Published

04 Jun 2026 12:06

Source

MarketWatch

TradingView Direct company coverage

Can AstraZeneca's Expanding Cancer Portfolio Sustain Momentum?

AstraZeneca's oncology segment, contributing 44% of total product sales, is a primary growth driver, with strong demand for drugs like Tagrisso, Lynparza, and Enhertu. The company is strengthening its portfolio through label expansions and advancing a deep late-stage pipeline, in

Tone

Positive 71/100

Event

Macro sensitivity

Published

03 Jun 2026 22:09

Source

TradingView

Proactive financial news Direct company coverage

Leading Bank maintains sell on AstraZeneca at 11,500p as ASCO glow fails to resolve key pipeline questions

Deutsche Bank has reiterated its "sell" rating and 11,500p price target for AstraZeneca, despite positive data presented at the ASCO conference. The bank acknowledges AstraZeneca's strong oncology record but remains cautious due to unresolved questions regarding regulatory approv

Tone

Negative 37/100

Event

Analyst action

Published

03 Jun 2026 20:32

Source

Proactive financial news